13F-HR: Johnson & Johnson's Q1 2025 13F Filing Reveals Significant Biotech Investments
13F Holdings Report
Johnson & Johnson's Q1 2025 13F filing discloses its holdings, with a total value of approximately $341.9 million, primarily focused on biotech companies.
Summary
- Johnson & Johnson filed its Form 13F for the quarter ended March 31, 2025.
- The filing reveals the company's holdings as an institutional investment manager.
- The total value of the reported holdings amounts to approximately $341.9 million.
- The portfolio includes investments in various biotech companies, including Adicet Bio, Arrowhead Pharmaceuticals, and others.
- Johnson & Johnson Innovation JJDC, Inc. is listed as another included manager.
- The filing reports a total of 20 entries in the Form 13F Information Table.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The filing indicates active investment in the biotech sector, which is generally viewed favorably. The large portfolio value and diverse holdings suggest a stable and strategic investment approach.
Positives
- The filing indicates active investment in the biotechnology sector, potentially driving innovation and growth.
- The diverse portfolio suggests a strategic approach to investment across different biotech companies.
- The significant value of holdings in companies like Protagonist Therapeutics and CVRx indicates confidence in their potential.
Industry Context
The filing reflects Johnson & Johnson's continued interest in the biotechnology sector, aligning with industry trends of pharmaceutical companies investing in innovative biotech firms for drug development and technological advancements.
Stakeholder Impact
- Shareholders may view the active investment strategy positively, as it indicates a focus on growth and innovation.
- The investments can support the growth and development of the portfolio companies, potentially leading to job creation and advancements in healthcare.
Key Dates
| Date | Description |
|---|---|
| 03-31-2025 | Report for the Calendar Year or Quarter Ended |
| 05-07-2025 | Date of Signing |
Keywords
13F filing, Johnson & Johnson, biotech, investments, holdings, portfolio
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.